Evidence map›Paper›PMID 28532456›Full record

ArticleBMC cancer2017

Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.

Xiaojing Li, Zhifeng Li, Xianping Li, Baoguo Liu, Zhijun Liu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Salviolone fromInternational journal of molecular sciences · 2022
    Article
  7. Review
  8. Frontiers in pharmacology · 2022
    Review
  9. Article
  10. Article
  11. An overview of the anti-cancer actions of Tanshinones, derived fromExploration of targeted anti-tumor therapy · 2020
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Anti-Adipogenic Effects on 3T3-L1 Cells and Zebrafish by Tanshinone IIA.International journal of molecular sciences · 2017
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiaojing LiDepartment of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei Province, 056002, People's Republic of China.
Zhifeng LiDepartment of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei Province, 056002, People's Republic of China.
Xianping LiDepartment of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei Province, 056002, People's Republic of China.
Baoguo LiuDepartment of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei Province, 056002, People's Republic of China. LBG66@163.com.
Zhijun LiuDepartment of Dermatology, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei Province, 056002, People's Republic of China. dermatology_good@126.com.
Affiliated Hospital of Hebei University · CNHebei University of Engineering · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant melanoma (MM) is one of the high degree of malignancy and early prone to blood and lymph node metastasis. There is not cured for MM. Tan II A has been reported to reduce cancer cell proliferation. But the mechanism by which Tan II A inhibited melanoma growth are not well characterized. We sought to explore the possible mechanism by which Tan II A regulated cell proliferation through autophagy signaling pathway in A375 cells.

methodsWe tested the effects of Tan II A on melanoma A375, MV3, M14, and other human cell lines including Hacat and HUVEC cells in cell culture model. Cell proliferation was assessed by using methyl thiazol tetrazolium (MTT) assay. Cell migration ability melanoma A375 was monitored by using cell scratch assay. Transwell chamber experimental was performed to assess the effect of Tan II A on A375 melanoma cell invasion ability. The autophagy body was examined by using flow cytometry. The expression of autophagy-associated protein beclin-1 and microtubule-associated protein 1 light chain 3(LC3)-II, as well as phosphatidylinositol 3-kinase(PI3K)、protein kinase B (Akt)、mammalian target of rapamycin (mTOR)、p70S6K1 signaling pathways were detected by using Western blotting. The effects of Tan II A on tumor progression was also examined in melanoma A375 induced tumor in mouse model.

resultsWe found that Tan IIA inhibited melanoma A375, MV3, and M14 cell proliferation in dose and time dependent manner. Tan II A reduced CXCL12-induced A375 cell invasive ability and migration in a dose dependent manner. Tan IIA promoted autophagic body production and increased autophagy-associated protein beclin-1 and LC3-II expression in A375 cells. However, Tan IIA reduced the phosphorylation of PI3K, P-AKT, P-mTOR, and P-p7036k1. We also confirmed that Tan II A reduced melanoma A375 induced tumor volume and weight in mouse model.

conclusionsWe concluded that Tan II A reduced A375 cells proliferation by activation of autophagy production, blocked PI3K- Akt - mTOR - p70S6K1 signaling pathway, increased autophagic related gene beclin-1, LC3-II protein expressions and induced autophagocytosis. Tan II A inhibited melanoma A375 induced tumor development in mouse model.

Indexed as

AbietanesAnimalsAntineoplastic Agents, PhytogenicAutophagyCell Line, TumorCell MovementCell ProliferationChemokine CXCL12Gene ExpressionHumansMelanomaMice, Inbred BALB CMice, NudeSignal TransductionSkin NeoplasmsTumor BurdenAbietanesAntineoplastic Agents, PhytogenicChemokine CXCL12CXCL12 protein, humantanshinoneA375 cellAutophagyCell invasion and migrationMalignant melanoma (MM)Tanshinone II A

Identifiers

PMID28532456
PMCPMC5441012
OpenAlexW2619794512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.